0.97
-0.1499(-13.38%)
Currency In USD
| Previous Close | 1.12 |
| Open | 1.13 |
| Day High | 1.15 |
| Day Low | 0.93 |
| 52-Week High | 3.7 |
| 52-Week Low | 0.57 |
| Volume | 204,844 |
| Average Volume | 176,982 |
| Market Cap | 15,819 |
| PE | -0.38 |
| EPS | -2.58 |
| Moving Average 50 Days | 0.93 |
| Moving Average 200 Days | 1.12 |
| Change | -0.15 |
If you invested $1000 in Akari Therapeutics, Plc (AKTX) 10 years ago, it would be worth $2.1 as of September 29, 2025 at a share price of $0.97. Whereas If you bought $1000 worth of Akari Therapeutics, Plc (AKTX) shares 5 years ago, it would be worth $28.87 as of September 29, 2025 at a share price of $0.97.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Akari Therapeutics’ Preclinical Data Demonstrates the Potential of its Novel ADC Spliceosome Modulating Payload, PH1
GlobeNewswire Inc.
Sep 24, 2025 12:45 PM GMT
Data highlights ability of Akari’s ADC payload, PH1, to suppress the levels of the AR-V7 receptor that is responsible for driving hormone refractory prostate cancer progression No current therapies have proven to be effective in AR-V7 driven tumors B
Akari Therapeutics Announces Filing for New Patent for Novel ADC Platform Utilizing Spliceosome Payload PH1 for the Treatment of Cancer
GlobeNewswire Inc.
Sep 17, 2025 12:45 PM GMT
BOSTON and LONDON, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today announced that it has filed a provisional patent applica
Akari Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
GlobeNewswire Inc.
Sep 05, 2025 10:45 AM GMT
BOSTON and LONDON, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today announced that Abizer Gaslightwala, President and Chief